期刊
CELL
卷 182, 期 5, 页码 1271-+出版社
CELL PRESS
DOI: 10.1016/j.cell.2020.07.024
关键词
-
资金
- National Key Research and Development Project of China [2020YFC0842200, 2020YFA0707801, 2016YFD0500304]
- special grant from AMS [JK2020NC002]
- National Science Fund for Distinguished Young Scholars [81925025]
- Innovative Research Group from the NSFC [81621005]
- Innovation Fund for Medical Sciences from the Chinese Academy of Medical Sciences [2019-I2M-5-049]
There is an urgent need for vaccines against coronavirus disease 2019 (COVID-19) because of the ongoing SARS-CoV-2 pandemic. Among all approaches, a messenger RNA (mRNA)-based vaccine has emerged as a rapid and versatile platform to quickly respond to this challenge. Here, we developed a lipid nanoparticle-encapsulated mRNA (mRNA-LNP) encoding the receptor binding domain (RBD) of SARS-CoV-2 as a vaccine candidate (called ARCoV). Intramuscular immunization of ARCoV mRNA-LNP elicited robust neutralizing antibodies against SARS-CoV-2 as well as a Th1-biased cellular response in mice and non-human primates. Two doses of ARCoV immunization in mice conferred complete protection against the challenge of a SARS-CoV-2 mouse-adapted strain. Additionally, ARCoV is manufactured as a liquid formulation and can be stored at room temperature for at least 1 week. ARCoV is currently being evaluated in phase 1 clinical trials.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据